IP Library Granted Patent US 11,839,653
Granted Patent B2
US 11,839,653 · App. 16/806,323 · Granted Dec 12, 2023

Anti-TIM-3 antibodies and methods of use thereof

Inventors: Marc van Dijk (Bosch en Duin, NL); Ekaterina Vladimirovna Breous-Nystrom (Basel, CH); Nicholas Stuart Wilson (San Carlos, CA); Jeremy Dale Waight (Everett, MA); Dennis John Underwood (Boston, MA)
Assignee: AGENUS INC.
A61K39/395C07K16/2803C07K2317/34C07K2317/52C07K2317/565C07K2317/71C07K2317/732C07K2317/76C07K2317/77C07K2317/92C07K2317/94C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,839,653
App. No.
16/806,323
Granted
Dec 12, 2023
Kind
B2
Abstract

Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Claims (50)

1. An isolated polynucleotide encoding a heavy chain variable region (VH) comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 comprising the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3; 4, 2, and 3; 5, 2, and 3; 6, 2, and 3; 7, 2, and 3; 8, 2, and 3; 9, 2, and 3; 10, 2, and 3; 11, 2, and 3; or 12, 2, and 3, respectively, and/or a light chain variable region (VL) comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 comprising the amino acid sequences set forth in SEQ ID NOs: 14, 21, and 22; or 15, 18, and 22, respectively.

2. The isolated polynucleotide of claim 1 , wherein the isolated polynucleotide encodes a heavy chain comprising the VH and/or a light chain comprising the VL.

3. The isolated polynucleotide of claim 1 , wherein the CDRH1, CDRH2, and CDRH3, comprise the amino acid sequences set forth in SEQ ID NOs: 5, 2, and 3, respectively, and the CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences set forth in SEQ ID NOs: 14, 21, and 22, respectively.

4. The isolated polynucleotide of claim 1 , wherein the VH comprises an amino acid sequence which is at least 75% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 24-35, and the VL comprises an amino acid sequence which is at least 75% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 36-47.

5. The isolated polynucleotide of claim 1 , wherein the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 24-35, and the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 36-47.

6. The isolated polynucleotide of claim 1 , wherein the VH and VL, respectively, comprise the amino acid sequences set forth in SEQ ID NOs: 24 and 36; 24 and 38; 26 and 42; 24 and 42; 24 and 46; 24 and 43; 26 and 43; 26 and 46; 26 and 41; 24 and 41; 25 and 39; 24 and 47; 25 and 40; 26 and 47; 25 and 37; 25 and 45; 25 and 44; 25 and 46; 25 and 42; 25 and 41; 25 and 43; 25 and 47; 27 and 46; 28 and 46; 29 and 46; 30 and 46; 31 and 46; 32 and 46; 33 and 46; 34 and 46; or 35 and 46.

7. The isolated polynucleotide of claim 1 , wherein the VH and VL, respectively, comprise the amino acid sequences set forth in SEQ ID NOs: 28 and 46.

8. The isolated polynucleotide of claim 2 , wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 57-68, and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 69.

9. The isolated polynucleotide of claim 2 , wherein the heavy chain and the light chain, respectively, comprises the amino acid sequences set forth in SEQ ID NOs: 57 and 69, 58 and 69, 59 and 69, 60 and 69, 61 and 69, 62 and 69, 63 and 69, 64 and 69, 65 and 69, 66 and 69, 67 and 69, or 68 and 69, respectively.

10. The isolated polynucleotide of claim 2 , wherein the heavy chain and the light chain, respectively, comprise the amino acid sequences set forth in SEQ ID NOs: 61 and 69, respectively.

11. A vector comprising:

(a) the polynucleotide of claim 1 ; or

(b) a first polynucleotide encoding the VH of the antibody set forth in claim 1 , and a second polynucleotide encoding the VL of the antibody set forth in claim 1 .

12. A host cell comprising:

(a) the polynucleotide of claim 1 ;

(b) a first polynucleotide encoding the VH of the antibody set forth in claim 1 , and a second polynucleotide encoding the VL of the antibody set forth in claim 1 ; or

(c) a first vector comprising a first polynucleotide encoding the VH of the antibody set forth in claim 1 , and a second vector comprising a second polynucleotide encoding the VL of the antibody set forth in claim 1 .

13. A method of producing an antibody, comprising culturing the host cell of claim 12 so that the polynucleotide is expressed and the antibody is produced.

14. A vector comprising:

(a) the polynucleotide of claim 2 ; or

(b) a first polynucleotide encoding the heavy chain of the antibody set forth in claim 2 , and a second polynucleotide encoding the light chain of the antibody set forth in claim 2 .

15. A host cell comprising:

(a) the polynucleotide of claim 2 ;

(b) a first polynucleotide encoding the heavy chain of the antibody set forth in claim 2 , and a second polynucleotide encoding the light chain of the antibody set forth in claim 2 ; or

(c) a first vector comprising a first polynucleotide encoding the heavy chain of the antibody set forth in claim 2 , and a second vector comprising a second polynucleotide encoding the light chain of the antibody set forth in claim 2 .

16. A method of producing an antibody, comprising culturing the host cell of claim 15 so that the polynucleotide is expressed and the antibody is produced.

17. A vector comprising:

(a) the polynucleotide of claim 7 ; or

(b) a first polynucleotide encoding the VH of the antibody set forth in claim 7 , and a second polynucleotide encoding the VL of the antibody set forth in claim 7 .

18. A host cell comprising:

(a) the polynucleotide of claim 7 ;

(b) a first polynucleotide encoding the VH of the antibody set forth in claim 7 , and a second polynucleotide encoding the VL of the antibody set forth in claim 7 ; or

(c) a first vector comprising a first polynucleotide encoding the VH of the antibody set forth in claim 7 , and a second vector comprising a second polynucleotide encoding the VL of the antibody set forth in claim 7 .

19. A method of producing an antibody, comprising culturing the host cell of claim 18 so that the polynucleotide is expressed and the antibody is produced.

20. A vector comprising:

(a) the polynucleotide of claim 9 ; or

(b) a first polynucleotide encoding the heavy chain of the antibody set forth in claim 9 , and a second polynucleotide encoding the light chain of the antibody set forth in claim 9 .

21. A host cell comprising:

(a) the polynucleotide of claim 9 ;

(b) a first polynucleotide encoding the heavy chain of the antibody set forth in claim 9 , and a second polynucleotide encoding the light chain of the antibody set forth in claim 9 ; or

(c) a first vector comprising a first polynucleotide encoding the heavy chain of the antibody set forth in claim 9 , and a second vector comprising a second polynucleotide encoding the light chain of the antibody set forth in claim 9 .

22. A method of producing an antibody, comprising culturing the host cell of claim 21 so that the polynucleotide is expressed and the antibody is produced.

23. A vector comprising:

(a) the polynucleotide of claim 10 ; or

(b) a first polynucleotide encoding the heavy chain of the antibody set forth in claim 10 , and a second polynucleotide encoding the light chain of the antibody set forth in claim 10 .

24. A host cell comprising:

(a) the polynucleotide of claim 10 ;

(b) a first polynucleotide encoding the heavy chain of the antibody set forth in claim 10 , and a second polynucleotide encoding the light chain of the antibody set forth in claim 10 ; or

(c) a first vector comprising a first polynucleotide encoding the heavy chain of the antibody set forth in claim 10 , and a second vector comprising a second polynucleotide encoding the light chain of the antibody set forth in claim 10 .

25. A method of producing an antibody, comprising culturing the host cell of claim 24 so that the polynucleotide is expressed and the antibody is produced.

Assignments (4)
SECURITY INTEREST Recorded Mar 31, 2025
From: AGENUS, INC.
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070680/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: VAN DIJK, MARC; BREOUS-NYSTROM, EKATERINA VLADIMIROVNA
To: AGENUS SWITZERLAND INC.
Reel/Frame 052083/0979 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: AGENUS SWITZERLAND INC.
To: AGENUS INC.
Reel/Frame 052084/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: WILSON, NICHOLAS STUART; WAIGHT, JEREMY DALE; UNDERWOOD, DENNIS JOHN
To: AGENUS INC.
Reel/Frame 052084/0163 →
Continuity (4)
Division 15606148 · May 26, 2017
Provisional Application 62420276 · Nov 10, 2016
Provisional Application 62342610 · May 27, 2016
Related Publication 20200297841A1 · Sep 24, 2020